The year 2025 marked a significant turning point for the Indian pharmaceutical sector with GST reforms and the Research Development Incentive (RDI) Scheme, according to industry experts. Over the past 25 years, the industry has grown from $3 billion to $60 billion, emphasizing the importance of innovation, quality, and enhanced access for future growth.
Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance, highlighted the transformative nature of 2025 for Indian pharma. Notable policy milestones such as the next-gen GST reform have enhanced affordability and widened patient access to medications, positioning the industry for further growth.
The implementation of revised Schedule M guidelines underscores the government’s commitment to quality, aligning India with global standards. Additionally, regulatory reforms and initiatives like Viksit Bharat 2047 aim to streamline business operations, laying a strong foundation for the industry’s future growth trajectory.
The introduction of the PRIP scheme has been well-received by the industry, marking a significant beginning towards fostering innovation. Leading Indian pharmaceutical companies are increasingly focusing on acquiring high-value products, securing regulatory approvals for advanced drugs, and closing licensing deals, reflecting a shift towards innovation in the sector.
Ameera Shah, President of NATHEALTH, observed a transformative shift in India’s healthcare sector in 2025. The sector witnessed a transition from illness-focused to wellness-centric approaches, fragmented care to integrated pathways, and digital adoption to digital intelligence, with AI playing a pivotal role in reshaping clinical workflows and enhancing decision-making processes.
Experts anticipate that healthcare will experience a pivotal decade in 2026, emphasizing the importance of innovation and expanded access for global leadership. The upcoming years are crucial for translating policy momentum into tangible outcomes, aiming to propel India’s healthcare industry towards a $450-500 billion mark by 2047 and establish itself as a global life sciences innovation hub.
As key therapies lose patent protection and new care models emerge, India has the opportunity to enhance access and assert global leadership. The focus for the future lies in leveraging technological advancements to drive measurable health impacts, ensuring that innovation not only boosts efficiency but also enhances equity and patient outcomes.
